Lindbrook Capital LLC Raises Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Lindbrook Capital LLC boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 54.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,580 shares of the medical research company’s stock after purchasing an additional 554 shares during the quarter. Lindbrook Capital LLC’s holdings in Agilent Technologies were worth $220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Kepos Capital LP boosted its holdings in shares of Agilent Technologies by 3.5% in the 3rd quarter. Kepos Capital LP now owns 2,775 shares of the medical research company’s stock worth $310,000 after purchasing an additional 93 shares in the last quarter. Rosenberg Matthew Hamilton grew its position in Agilent Technologies by 51.1% during the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 96 shares during the last quarter. Invesco LLC raised its stake in shares of Agilent Technologies by 0.7% during the third quarter. Invesco LLC now owns 15,471 shares of the medical research company’s stock worth $1,730,000 after acquiring an additional 101 shares in the last quarter. Balentine LLC lifted its holdings in shares of Agilent Technologies by 3.4% in the 3rd quarter. Balentine LLC now owns 3,180 shares of the medical research company’s stock worth $356,000 after acquiring an additional 104 shares during the last quarter. Finally, Sonen Capital LLC lifted its holdings in shares of Agilent Technologies by 3.6% in the 3rd quarter. Sonen Capital LLC now owns 3,050 shares of the medical research company’s stock worth $341,000 after acquiring an additional 105 shares during the last quarter.

Agilent Technologies Price Performance

A stock opened at $133.91 on Tuesday. The firm has a 50-day moving average of $141.21 and a 200 day moving average of $130.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The company has a market cap of $39.24 billion, a P/E ratio of 31.88, a PEG ratio of 4.02 and a beta of 1.11. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $151.58.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm’s revenue for the quarter was down 5.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.37 EPS. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.51 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be given a dividend of $0.236 per share. The ex-dividend date of this dividend is Monday, April 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.70%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.38%.

Insider Buying and Selling at Agilent Technologies

In other news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,610 shares of company stock valued at $9,220,333.

Analyst Ratings Changes

A number of equities analysts recently commented on A shares. Barclays lifted their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Stifel Nicolaus upgraded Agilent Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $145.00 to $163.00 in a report on Friday, April 5th. Oppenheimer boosted their target price on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Evercore ISI raised their price target on Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, UBS Group lifted their price target on Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $141.29.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.